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Abstract
Background: Regular laboratory test monitoring of patient parameters offers a route for improving the quality of
chronic disease care. We evaluated the effects of brief educational messages attached to laboratory test reports on
diabetes care.
Methods: A programme of cluster randomised controlled trials was set in primary care practices in one primary
care trust in England. Participants were the primary care practices’ constituent healthcare professionals and patients
with diabetes. Interventions comprised brief educational messages added to paper and electronic primary care
practice laboratory test reports and introduced over two phases. Phase one messages, attached to Haemoglobin
A1c (HbA1c) reports, targeted glycaemic and cholesterol control. Phase two messages, attached to albumin:
creatinine ratio (ACR) reports, targeted blood pressure (BP) control, and foot inspection. Main outcome measures
comprised practice mean HbA1c and cholesterol levels, diastolic and systolic BP, and proportions of patients
having undergone foot inspections.
Results: Initially, 35 out of 37 eligible practices participated. Outcome data were available for a total of 8,690
patients with diabetes from 32 practices. The BP message produced a statistically significant reduction in diastolic
BP (-0.62 mmHg; 95% confidence interval -0.82 to -0.42 mmHg) but not systolic BP (-0.06 mmHg, -0.42 to 0.30
mmHg) and increased the odds of achieving target BP control (odds ratio 1.05; 1.00, 1.10). The foot inspection
message increased the likelihood of a recorded foot inspection (incidence rate ratio 1.26; 1.18 to 1.36). The
glycaemic control message had no effect on mean HbA1c (increase 0.01%; -0.03 to 0.04) despite increasing the
odds of a change in likelihood of HbA1c tests being ordered (OR 1.06; 1.01, 1.11). The cholesterol message had no
effect (decrease 0.01 mmol/l, -0.04 to 0.05).
Conclusions: Three out of four interventions improved intermediate outcomes or process of diabetes care. The
diastolic BP reduction approximates to relative reductions in mortality of 3% to 5% in stroke and 3% to 4% in
ischaemic heart disease over 10 years. The lack of effect for other outcomes may, in part, be explained by
difficulties in bringing about further improvements beyond certain thresholds of clinical performance.
Trial Registration: Current Controlled Trials, ISRCTN2186314.
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Background
Despite continuing improvements in the delivery and
outcomes of care for people with diabetes [1-3] there is
still evidence of substantial inappropriate variations
[4-8]. A systematic review of quality improvement stra-
tegies for patients with type 2 diabetes indicated small
to modest effects on glycaemic control [9]. Much work
remains to be done in developing and evaluating many
quality improvement strategies given that they are often
resource-intensive and the difficulties in reliably identi-
fying their ‘active ingredients’ [10].
Across a range of different targeted clinical behaviours
and contexts, in general reminders delivered to health-
care professionals consistently improve performance
[11], an effect also apparent with point-of-care computer
reminders [12]. However, the optimal configuration of
such reminders is still unclear. One approach that offers
the potential advantages of simplicity and sustainability
is attaching brief educational messages to the results of
tests ordered in the expectation that the healthcare pro-
fessional who ordered the test will read and act on the
message when the result is delivered back to the prac-
tice. Attached to radiology reports ordered from primary
care, such an intervention reduced requests for targeted
x-rays without compromising quality of referrals [13].
Messages attached to test reports also reduced primary
care laboratory test requests [14].
However, previous research on interventions to
change test ordering-related behaviour has largely
focused on either decreasing the overall volume of tests
ordered (in the implicit belief that some are unneces-
sary) or specifically decreasing the number of inap-
propriate tests ordered; 47 out of 49 studies in one
review focused on such reductions [15]. Less is known
about the effectiveness of test ordering messages in
improving wider aspects of clinical management to pro-
mote evidence-based care.
In one primary care trust in the north east of England,
we evaluated the effects on the care provided for
patients with type 2 diabetes of educational prompts
attached to laboratory test reports and aimed at increas-
ing evidence-based clinical practice.
Methods
Study design
The study used a cluster randomised controlled trial
design, described in detail elsewhere [16], with primary
care practices as the unit of randomisation.
Participants, setting and context
The study participants were the clinicians–general prac-
titioners (GPs) and nurses–working in those primary
care practices in Newcastle upon Tyne that used the
laboratory services of the Newcastle Hospitals NHS
Trust (now the Newcastle Hospitals NHS Foundation
Trust). Outcomes were assessed on all those patients
registered with each practice and with a diagnosis of
diabetes whose care was undertaken either by the prac-
tice or shared between the practice and hospital.
The study started in late 2005, one year after the
advent of performance-related funding for primary care
physicians [17]. Through the Quality and Outcomes Fra-
mework (QOF), practices earned points for achieving
targets across a range of clinical and organisational indi-
cators. Performance against these targets can generate
up to 40% of practice income. The QOF initially
included 18 diabetes indicators that were extended or
modified over subsequent years [18].
Interventions
The interventions were four brief educational messages,
typically of less than 30 words, added to the returned
results of laboratory tests ordered by clinicians on
patients with diabetes cared for in intervention practices.
The educational messages were developed by a multi-
disciplinary group that included clinical representatives
from primary care, secondary care, laboratory services,
and the research team. The messages gave succinct evi-
dence-based, educational information regarding appro-
priate patient management congruent with the local
diabetes clinical guideline (Table 1). The message topics
were selected because of their clinical importance, and
the feasibility of being able to measure improvements in
relevant outcomes from routinely held data in primary
care practices.
The interventions were introduced in two phases. In
phase one (December 2005), messages were attached to
electronic and paper Haemoglobin A1c (HbA1c) test
reports. The messages were of two types. The first mes-
sage related to glycaemic control, was conditional on
the HbA1c level, and gave advice about appropriate
treatment. The second type of message gave a non-con-
ditional message relating to cholesterol control.
In phase two (October 2006), messages were attached
to albumin:creatinine ratio (ACR) test reports and were
also of two types. The first message related to blood
pressure (BP) control, was conditional on the ACR level,
and gave advice on target BP levels for patients with
and without a diagnosis of microalbuminuria. The sec-
ond message related to foot inspection and was non-
conditional.
Intervention fidelity
We contacted at least two practices in each of the four
study arms at six-month intervals (different practices
each time) to check whether practices were receiving
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their allocated messages, and that the messages contin-
ued over the intervention period as planned
Randomisation
In each of two phases primary care practices were ran-
domised twice to receive or not each of two educational
messages. Thus, in each phase 25% of practices received
both messages, 25% each received one of the messages,
and 25% received no intervention. For phase one, pri-
mary care practices were randomised twice to receive or
not the glycaemic educational messages and to receive
or not the cholesterol educational messages. Randomisa-
tion was stratified using existing routine data by both
the number of patients with diabetes per practice (using
a median split of 200) and the proportion of patients
with an HbA1c of 7.4% or less (grouped by less than
60%, 60% to 70%, and over 70%) [17].
For phase two, ten months later, practices were rando-
mised twice to receive or not the foot inspection remin-
der message and to receive or not the BP educational
messages. On this occasion randomisation was stratified
by practice QOF scores for recorded foot examination
(median split of 2.85 points out of 3) and the proportion
of patients with a record of BP of 145/85 mmHg or less
(using median split of 74.8%). All randomisations were
conducted independently by a statistician using numbers
randomly generated by computer.
Outcomes
The main outcomes were the primary care practices’
mean levels of HbA1c, cholesterol and BP, and numbers
of patients with recorded foot inspections in the pre-
vious calendar month. Other analysed outcomes were:
the number of patients within target ranges for HbA1c,
cholesterol, and BP; the number of HbA1c, cholesterol,
and ACR tests requested (standardised for practice size);
and mean practice BP levels for patients with and with-
out recorded microalbuminuria (operationalised as a
record of two or more consecutive ACRs of 2.5 or
greater).
Data collection
National Health Service (NHS) staff collected coded data
from practice computer systems using customised elec-
tronic queries. They were not blinded to group assign-
ment. They removed patient identifiers before the
transfer of data to the research team. For phase one
interventions, there were 24 and 34 months of pre- and
post-intervention outcome data, respectively, whilst for
phase two interventions, there were similarly 34 and 24
months of data. This produced multiple observations for
patients over the study. In general, practices routinely
collect and code patient data that contribute to the cal-
culation of scores for the QOF [17]. Our data were simi-
lar (though not identical) to these and within QOF
practices are subject to independent scrutiny of their
data for accuracy and completeness, thereby allowing a
considerable degree of confidence in data quality,
though we did not independently assess this.
Sample size
The sample size calculations, based on methods
described by Donner et al. [19], were undertaken using
a programme developed by Campbell et al. [20]. They
were based upon the following assumptions: 34 partici-
pating practices each with a mean number of 62
patients with diabetes; a significance level of 5%; 80%
power; and an intra-class correlation coefficient (ICC) of
Table 1 Content of the laboratory test messages
Study
phase
Type and attachment of message Content of message
Phase
One
Unconditional; attached to all cholesterol reports For type 2 diabetes and age ≥ 40 yrs: on simvastatin 40 mg? See [local
guideline] for detail and exclusions
Conditional; attached to all HbA1c reports If HbA1c < 6.5%
’Within target for type 2 diabetes’
If HbA1c 6.5 to 7.0%
’For type 2 diabetes, consider increasing oral therapy’
If HbA1c 7.0 to 8.0%
’If type 2 diabetes: on max oral therapy, e.g., Metformin 1G BD + gliclazide 160
mg BD?’
If HbA1c > 8.0%
’If type 2 diabetes, consider insulin if on max oral Rx, e.g., Metformin 1G BD +
gliclazide 160 mg BD’
Phase
Two
Unconditional; attached to all albumin: creatinine ratio
(ACR) test reports
’Newcastle Diabetes Guideline Footcare: all patients annual review of sensation,
pulses, footwear education’
Conditional; attached to all ACR test reports If ACR above 2.5
’If confirmed microalbuminuria: aim for BP < 130/80 in type 2 diabetes’
If ACR below 2.5
’If no microalbuminuria: aim for BP control < 140/80 in type 2 diabetes’
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0.2 for process measures (based upon recording of blood
pressure and HbA1c for an earlier trial [21]) and 0.05
for intermediate outcomes [22]. With these assumptions,
we would be able to detect a 21% improvement (from
55% to 76%) in a binary outcome measure (e.g., foot
examination) and an effect size of 0.25 in a continuous
outcome measure. The latter represents changes of
0.36% in mean HbA1c, 0.27 mmol/L in mean choles-
terol, 4.98 mmHg in mean systolic BP, and 2.55 mmHg
in mean diastolic BP.
Analysis
The analytic strategy differed from that given in the
published protocol [16]. First, we were able to run the
study over a longer period than initially anticipated, giv-
ing us the opportunity to capitalise on the fact that we
could collect data over an extended period of time. An
interrupted time series analysis approach allowed use of
all the available data rather than reducing them to single
observations per patient pre- and post-intervention [23].
Second, analyses were also adjusted to take account of
factors used to stratify randomisation.
Only observations made after a patient was first diag-
nosed with diabetes were included in the analysis. For con-
tinuous dependent variables (BP, HbA1c and cholesterol
values), a three-level, multilevel model incorporating ran-
dom variation between practices, random variation
between patients within practices, and random variation
between repeated measures within patients was used to
investigate the impact of the interventions. The following
fixed effects were investigated: general trends in the
dependent variable over time; a difference between inter-
vention and control practices across the entire period of
investigation; and a difference between observations made
prior to the relevant intervention and those made after.
Fitting an interaction between the last two effects then
provided an estimate of the effect of the intervention.
The continuous variables were also dichotomised:
patients were categorised as being above (not controlled)
or below (controlled) target thresholds described in the
educational messages. These binary variables were ana-
lysed using a three-level, multilevel model as described
above except that a binomial error structure was assumed
for the random variation at the lowest level of the model.
To investigate the effect of the intervention on rates of
foot inspection and rates of test ordering, the dependent
variable was the number of patients for whom a foot
inspection or test result was recorded in a practice in a
calendar month. This was analysed using a two-level,
negative binomial regression model with months nested
within practices. The log of the number of patients with
diabetes in the practice during the month was included
as an offset. The effects of the interventions were then
estimated using the approach described above for the
continuous variables.
Ethical approval
The study was approved by the Newcastle and North
Tyneside Research Ethics Committee (Reference number
05/Q0905/95).
Results
Of 37 eligible practices, 35 agreed to participate and two
declined. By the time of outcome data collection, two
practices had merged into one (both cholesterol mes-
sage-only practices at first randomisation, whilst one
received both messages and one foot inspection mes-
sages only at second randomisation) and a further prac-
tice had closed (glycaemic and cholesterol messages
only). Following inspection, clinical data were consid-
ered unusable for one control practice (which appeared
to be using HbA1c as a diagnostic as well as monitoring
test) and it was therefore excluded from the analysis.
Thus outcome data were available for 32 practices. We
identified a total of 8,690 patients with diagnoses of type
2 diabetes made before or during the study period.
Table 2 shows the baseline characteristics of study prac-
tices and their patients. The CONSORT diagrams (Fig-
ures 1 and 2) summarise the flows of recruitment,
participation, and analysis.
We checked with 18 practices as to whether they were
receiving allocated interventions. For the eight various
possible combinations of the four intervention messages,
at least two practices per combination confirmed receipt
of the messages as allocated. There were no cases of
practices receiving an unallocated message.
The mean intra-cluster correlations (ICCs) at baseline
were 0.03 (95% CI: 0.02, 0.05) for HbA1c, 0.04 (0.02,
0.07) for systolic BP, 0.02 (0.01, 0.03) for diastolic BP,
and 0.06 (0.03, 0.1) for cholesterol. For foot inspection,
the corresponding figures were 0.34 (0.28, 0.53), reflect-
ing large systematic differences between practices in the
recording of this variable.
In general, the clinical values were already reasonable,
with baseline control group mean values of HbA1c of
7.4%, cholesterol of 4.5 mmol/l, and BP of 147/80
mmHg. Figures 3, 4 and 5 show the intervention and
control trends in their values over the study period.
Table 3 shows the estimated effects of the interventions
based on the multilevel models.
There was no intervention effect on HbA1c (increase
0.1%; 95% CI -0.03, 0.04) or good glycaemic control
(HbA1c less than 6.35%; OR 0.94; 95% 0.87, 1.03). How-
ever, the intervention produced an increase in the likeli-
hood of a test being ordered (IRR 1.06; 95% CI 1.01, 1.11).
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There was no intervention effect on mean cholesterol
levels, whether or not cholesterol was within target
range or cholesterol testing rates.
For systolic BP, there was a mean annual reduction of
1.59 (95% CI 1.49, 1.69) mmHg during the study period,
but no intervention effect. For diastolic BP, there was a
mean annual reduction of 0.92 (95% CI 0.81, 1.02)
mmHg during the study period, and a statistically signif-
icant reduction (-0.52 (95% CI -0.73, -0.32) mmHg in
intervention practices. The intervention increased the
odds of patient BP being controlled at or under 140/80
(OR 1.05 (95% CI 1.00, 1.10).
For the BP analyses, we also considered the possibility
of a delayed effect given the time taken for clinical
review and treatment titration of patients with raised
BP. We therefore undertook an exploratory post hoc
analysis, fitting a delayed effect to the model that
assumed a gradual increase in the intervention effect
Table 2 Pre-intervention characteristics of intervention and control groups.
Trial intervention Pre-intervention characteristics Intervention group Control group
Glycaemic control Practice factors
Number 18 16
Median number of partners 4.5 4
Mean (SD) list size 7,082 (3150) 8,170 (7071)
Patient factors
Mean (SD) number in practice 196 (108) 205 (120)
Mean age (years, SD) 65 (14) 63 (14)
Proportion men (%) 52 53
Mean (last recorded) HbA1c (SD) 7.4 (1.4) 7.4 (1.4)
Cholesterol control Practice factors
Number 18 16
Median number of partners 4 4
Mean (SD) list size 7,455 (7049) 7,775 (2890)
Patient factors
Mean (SD) number in practice 188 (109) 213 (117)
Mean age (years, SD) 64 (14) 64 (14)
Proportion men (%) 52 53
Mean (last recorded) cholesterol (mmol/l) 4.7 (1.2) 4.5 (1.1)
Blood pressure control Practice factors
Number 17 17
Median number of partners 5 4
Mean (SD) list size 7,433 (3085) 8,117 (6971)
Patient factors
Mean (SD) number in practice 239 (128) 200 (116)
Mean age (years, SD) 65 (14) 63 (14)
Proportion men (%) 53 53
Mean (last recorded) systolic BP (mmHg) 145 147
Mean (last recorded) diastolic BP (mmHg) 80 80
Foot examination Practice factors
Number 17 17
Median number of partners 4 4
Mean (SD) list size 7,449 (3188) 8,133 (7015)
Patient factors
Mean (SD) number in practice 223 (105) 218 (139)
Mean age (years, SD) 64 (14) 64 (14)
Proportion men (%) 51 54
Proportion with a recorded foot inspection in the previous 15 months (%) 2536 (69) 2761 (78)
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Glycaemic control message         Cholesterol control message  
  
    
   
Eligible and invited (37 practices)
2 practices declined
Randomised (35 practices)
Intervention group 
(18 practices)
Practice list size:
Mean = 7082
(SD = 3150)
Lost to FU: 0
Control group 
(17 practices)
Practice list size:
Mean = 8170 
(SD = 7071)
Lost to FU: 0
Clusters analysed: 17
Excluded: 0
Lost to follow up: 1 
practice closed
Patients: 4240
Patients analysed: 4240
Excluded: 0
Clusters analysed: 15
Excluded: 1 
(unreliable data)
Merged: 2 practices into 1
Patients: 4450
Patients analysed: 4450
Excluded: 0
Eligible and invited (37 practices)
2 practices declined
Randomised (35 practices)
Intervention group 
(18 practices)
Practice list size:
Mean = 7455
(SD = 7049)
Lost to FU: 0
Control group 
(17 practices)
Practice list size:
Mean = 7775
(SD = 2890)
Lost to FU: 0
Clusters analysed: 16
Excluded: 0
Merged: 2 practices into 1
Lost to follow up: 1 practice 
closed
Patients: 4361
Patients analysed: 4361
Clusters analysed: 16
Excluded: 1 
(unreliable data)
Patients: 4329
Patients analysed: 4329
Excluded: 0
Figure 1 CONSORT flow charts for Phase One.
Blood pressure control message (Diastolic & Systolic)      Foot examination message
Eligible (35 practices) 
0 declined 
2 practices merged 
Randomised (34 practices)
Intervention group  
(17 practices)
Practice list size: 
Mean = 7433 
(SD = 3085) 
Lost to FU: 0 
Control group  
(17 practices)
Practice list size: 
Mean = 8117   
(SD = 6971) 
Lost to FU: 0
Clusters analysed: 17 
Excluded: 0 
Patients: 4061 
Patients analysed: 3937 
Excluded: 124 (no pre-
intervention data)
Clusters analysed: 15 
Excluded: 1  
(unreliable data) 
Patients: 3207 
Patients analysed: 3086 
Excluded: 121 (no pre-
intervention data) 
993
4 93
0
Eligible (35 practices) 
Lost to follow up: 1  
: 3697 
Patients analysed: 3697 
Excluded: 0
0 declined 
2 practices merged 
Randomised (34 practices)
Intervention group  
(17 practices)
Practice list size: 
Mean = 7449 
(SD = 3188) 
Lost to FU: 0 
Control group  
(17 practices)
Practice list size: 
Mean = 8133  
(SD = 7015) 
Lost to FU: 0
Clusters analysed: 16 
Excluded: 1  
(unreliable data) 
Patients: 4400 
Patients analysed: 4400 
Excluded: 0
Clusters analysed: 16 
Excluded: 0 
Lost to follow up: 1  
Patients: 4290 
Patients analysed: 4290 
Excluded: 0 
Figure 2 CONSORT flow charts for Phase Two.
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over a four month period. This analysis found no evi-
dence of a delayed effect.
For foot examination, there was an increased likeli-
hood of a recorded foot inspection (IRR 1.26; 95% CI
1.18, 1.36) in intervention practices.
The BP analyses planned for patients with microalbumi-
nuria were constrained by missing data because ACR
results were only available from a subset of 21 of the 32
practices included in the final analysis. In these 21 prac-
tices (comprising 14 and seven of the intervention and
control groups, respectively) there were 5,765 patients
who each contributed between one and 108 BP measure-
ments over the study period (79,135 measurements in
total). There were 1,019 patients with two or more conse-
cutive ACR values greater than 2.5 (18,358 BP measure-
ments in total corresponding to these patients). In patients
with microalbuminuria, mean systolic BP increased by
1.38 (0.33, 2.42) mmHg, whilst there was a non-significant
increase in diastolic BP of 0.61 (-0.03, 1.19) mmHg.
The intervention reduced the odds of a patient with
microalbuminuria having their blood pressure controlled
at or under 130/80 mmHg (OR 0.88; 95% CI 0.78, 0.99).
Discussion
Three of the four educational messages accompanying
laboratory test reports influenced clinical behaviour for
two primary outcomes (BP and foot inspections) and
one secondary outcome (HbA1c testing). Patient end-
points improved, with a small decrease in diastolic BP
and an increase in the proportion of patients with con-
trolled BP, and processes of care changed, with
increased likelihoods of recorded foot inspections and
HbA1c testing. Where they occurred, the effects
appeared immediately after initiation of the messages.
Once established, given its automated nature, this inter-
vention is likely to be easily sustainable. These effects
were achieved against a background of improving per-
formance accelerated by financial incentives [3]; the
average overall percentage level of achievement for the
QOF diabetes indicators had improved over 2005 to
2009 from 93.2% to 98.4% in England and from 97.9%
to 99.7% in Newcastle upon Tyne [18]. Furthermore, in
a recent comparative audit, the primary care trust in
Newcastle was ranked first out of 152 trusts in England
in having the highest percentage of people with diabetes
Figure 3 Mean HbA1c during period of study by calendar month.
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with blood pressure less than 145/85 mmHg [24]. This
makes the achievement of improving BP levels and con-
trol particularly notable. Against such background levels
of achievement in relation to the QOF (94% for check-
ing peripheral pulses in 2009 in Newcastle upon Tyne),
it would also be surprising if the increased likelihood of
foot inspection was merely attributable to better
recording.
Although how well foot inspection was performed is
unknown, the observed change is likely to represent a
true improvement in care. This is important given the
recognised value of multiple risk factor reduction,
including for vascular endpoints, in type 2 diabetes [25].
Previous studies of test-ordering messages have
demonstrated reductions in request rates [12-14]. This
is one of a very few studies aimed at improving appro-
priate care, and our interventions improved broader
aspects of clinical management and patient endpoints.
Furthermore, our evaluation on changes in physiological,
intermediate outcome, endpoints (rather than rate
changes) represented a more stringent test of the effect
of the interventions’ ability to improve patient care [26].
That the interventions changed both process and
intermediate outcome further supports the utility of this
method of improving patient care.
The acquisition of more clinical data than originally
planned allowed the detection of a statistically signifi-
cant smaller change in diastolic BP than the trial was
originally powered for. Although the small effect on
mean diastolic BP is unlikely to be clinically important
at an individual level, it approximates to worthwhile
population-level benefits. When the coefficients at ages
60 to 69 years from the Prospective Studies Collabora-
tion are applied [27], these diastolic BP reductions pro-
duce of the order of a 5% relative reduction in stroke
mortality and 3% to 4% falls in mortality from ischaemic
heart disease and other vascular causes over 10 years.
This mean population effect may be explained by GPs
targeting action on patients above the threshold of 140/
80 mmHg, as indicated by the increased odds of
patients’ BP being controlled in intervention practices.
The increase in HbA1c testing rates suggests that the
glycaemic control message influenced practice. Our
interpretation of this is that it reflects increased testing
in response to increased attempts to improve glycaemic
control. The absence of an effect on HbA1c levels may
Figure 4 Mean HbA1c during period of study by calendar month.
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partly reflect the wider range of physiological and com-
pliance issues around improving this endpoint and pos-
sible ‘ceiling effects’–the mean post-intervention HbA1c
for both control and intervention groups (7.5%) was
close to the then QOF target level of 7.4% or less.
Nonetheless, there is still scope for improvement given
that 37% of patients still had levels above this target.
More intensive and complex types of intervention may
be required to target this problem [9].
The result that the BP message led to worse control in
patients with microalbuminuria was unexpected and
counterintuitive. We were underpowered for the com-
parison because we had not anticipated that 11 of the
practices would not provide valid data, so the analysis
was based on about 1,000 patients from 21 practices
compared to the overall BP analysis that was based on
about 7,400 patients from 34 practices. BP control over
the entire period of the study was better for patients in
practices randomised to receive BP messages than for
those in control practices (difference in means of 3.7
and 2.7 mm Hg in systolic and diastolic BP, respec-
tively). Thus, there was less room for improvement in
practices that received the intervention. The observed
effect of the intervention may be a regression to the
mean phenomenon given the higher baseline values in
the practices that did not receive the BP messages.
There is also the possibility that there was something
systematically different about the 21 practices that did
and the 11 that did not contribute data to this analysis.
Taken together, our findings suggest that there may be
a threshold in clinical performance beyond which
prompts attached to test results do not work or have
only modest effects. The review of point-of-care compu-
ter reminders did not find any specific reminder or con-
textual features significantly associated with effect size
[12]. A review of a different behaviour change interven-
tion, audit, and feedback found that lower baseline levels
of clinical performance were associated with larger effect
size [28]. Therefore, brief educational messages may still
have considerable potential to improve practice and
merit further exploration in at least three ways. First,
their relative effects may vary across different levels of
baseline performance, and it is worth actively investigat-
ing the modifying effects of baseline performance. They
Figure 5 Mean systolic and diastolic BP during period of study by calendar month.
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may work best as an initial intervention where there
have been no previous efforts to improve performance
and levels of appropriate performance are relatively low.
Second, the impact of such interventions may be
strengthened by better adapting them more specifically
to clinician and patient needs [29,30]. The conditional
messages (HbA1c control and ACR/BP), where a speci-
fic clinical action was recommended on the basis of a
test result, were very simple and had mixed effects.
Third, many clinical decisions are based upon laboratory
results. The advent of real-time, interactive compu-
terised requesting and reporting systems provides
opportunities to readily identify candidate tests or con-
ditions and then to influence practice both as requests
are made and reports received, thereby allowing more
efficient targeting of test request messages.
Study strengths included the use of a randomised
design allowing us to be confident that any observed
effects could therefore be attributed to the interventions,
despite other quality improvement initiatives affecting
diabetes care during the time of the study [31,32]. We
are confident of fidelity given that our routine checks
on the messages received revealed no deviations from
randomised assignment. We used reliably coded data
with minimally intrusive data collection, conducted after
the intervention period was complete, that captured any
effects on whole practice populations, thereby prevent-
ing any selection bias attributable to differential recruit-
ment within randomised clusters [33]. We examined
long-term outcomes (at least 24 months), thereby
affording greater confidence in the sustainability of any
effects.
There were several limitations. First, the study took
place in one geographical area with limited patient eth-
nic diversity [34], so it is unclear how our results would
translate into a setting with a higher ethnicity-related
prevalence of diabetes. However, given that our trial
involved a population of primary care practices with
higher than average levels of performance for diabetes
care, our estimated effects may be relatively conservative
[18,24]. Second, practices on the borders of Newcastle
could also conceivably have used other hospital labora-
tories, thereby diluting intervention effects. However,
this is unlikely to be a major issue given that laboratory
services are usually arranged as part of block contracts
with local hospital services. Third, we do not know if
the messages were actually read by clinical practice staff,
especially by those responsible for acting upon results.
Fourth, as we assessed one main outcome for each of
four randomised interventions, we cannot rule out type
Table 3 Estimated impact of the interventions.
Outcome Effect of intervention
Parameter† Estimate‡ 95% CI
Glycaemic control message
HbA1c (%)* mean 0.01 -0.03 0.04
HbA1c within target level of control (less than 6.35) OR 0.94 0.87 1.03
Number of HbA1c tests being ordered in a calendar month IRR 1.06 1.01 1.11
Cholesterol control message
Cholesterol (mmol/l)* mean 0.01 -0.04 0.05
Cholesterol within target level of control (5 mmol/l or less) OR 1.01 0.92 1,11
Number of a cholesterol tests being ordered in a calendar month IRR 1.00 0.95 1.05
Blood pressure control message
Systolic blood pressure (mm Hg): all patients* mean -0.06 -0.41 0.30
Systolic blood pressure (mm Hg): patients with micro-albuminuria from 21 practices mean 1.38 0.33 2.42
Diastolic blood pressure (mm Hg): all patients* mean -0.52 -0.73 -0.32
Diastolic blood pressure (mm Hg): patients with micro-albuminuria from 21 practices mean 0.61 0.03 1.19
Blood pressure within target level of control (less than or equal to 140/80): all patients OR 1.05 1.00 1.10
Blood pressure within target level of control (less than or equal to 130/80): patients with micro-albuminuria OR 0.88 0.78 0.99
Foot inspection message
Number of patients in practice for whom a foot inspection was recorded in a calendar month* IRR 1.26 1.18 1.36
†Notes
• mean: change in mean that can be attributed to the intervention
• OR: odds ratio (relative increase in odds of stated outcome)
• IRR: incidence rate ratio (relative increase in likelihood of stated outcome)
‡ Estimates adjusted for strata used when randomising practices.
*Main outcome measure
Foy et al. Implementation Science 2011, 6:129
http://www.implementationscience.com/content/6/1/129
Page 10 of 12
1 error as an explanation for the statistically significant
effect on diastolic BP. Fifth, we did not perform an eco-
nomic analysis. Whilst the intervention had low set up
and negligible costs, any relative cost-effectiveness might
be reduced by increased test ordering (for HbA1c), pre-
scribing, or consultations. Finally, as an empirical inter-
vention, we do not have any insight into how or why
the intervention did or did not work. Further research is
needed to understand the processes by which apparently
simple interventions work.
Conclusion
Brief educational messages attached to laboratory test
results represent a simple and sustainable way to bring
about improvements in care. We have demonstrated
that messages aimed to improve care-produced effects
on clinical practice to varying degrees, including changes
in patient endpoints that may be worthwhile at a popu-
lation level. These changes occurred over and above the
background effects of a major pay-for-performance pro-
gramme for primary care practice in a geographical area
with historically high levels of performance. Given that
the vast majority of studies of this type of intervention
aim to decrease inappropriate test use, educational
prompts aimed at improving care merits further
research to identify the most appropriate clinical con-
texts where they can effectively target practice, explore
how they work and means of enhancing their effects,
and assess their cost-effectiveness.
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